SRTS

Sensus Healthcare Inc. (SRTS) | Rumor.io

Sensus Healthcare

SRTS

Attention (50-day avg)0%

Attention rank (50-day avg)#3,296

Bullish sentiment (50-day avg)100%

Price to earnings ratio49.5

Market capitalization49.3M

Earnings per share-0.94

Dividend yield (TTM)—

Revenue (annual)27.5M

Net income (annual)-7.7M

Social

What share of all stock conversation is about SRTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 13

Sensus Healthcare's (SRTS) Q42025 results fell short of market predictions, leading to a decline in stock price.
The decline is seen as positive for the company's future, as it reflects a strategic transition to diversified recurring models, including FDA treatments and direct sales.
Sensus Healthcare delivered 11,411 FDA treatments to 922 patients in 2025, a significant increase from 1,367 treatments delivered to 264 patients in 2024.

Generated by AI

Sentiment

Of the messages about SRTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.74% +2.4
Bearish	—	—	0% 0	5.26% -2.4

Bullish· Feb 6

The company's earnings report was "amazing" and the stock is expected to reach $10+ by the end of the year.
The company has a strong story, with near 0 dilution, no debt, and profitable quarters, and is navigating through hard times with a new FDA model that will take time to generate revenue.
The company's valuation is low, making it a buy despite the recent earnings report being lower than expected.

Bearish· Feb 6

Sensus Healthcare, Inc. ($SRTS) is expected to experience a lull in revenue due to its transition to the Fair Trade revenue-sharing model, with management providing no guidance on the timing of the ramp-up.
The company's reliance on a single customer, SkinCure, is a concern, as it limits the potential for growth and creates a vulnerable position if SkinCure were to seek alternative device sources.
Sensus Healthcare's earnings release was met with disappointment, as the company missed earnings estimates and guided to a weak Q1, with sales expected to grow year-over-year in 2025 but only in the second half of the year.

Generated by AI

Topics

Of the messages about SRTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	80%
Earnings	0%	0%	0%	12.86%
Analysts	0%	0%	0%	1.43%
Controversies	0%	0%	0%	2.86%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	2.86%

Earnings· Nov 5

Sensus Healthcare, Inc. (SRTS) to release earnings after market close on Wednesday, with analysts expecting -0.05 EPS.
Earnings release timing aligns with market close on Wednesday.
Analysts' earnings expectations for SRTS are -$0.05 EPS.

Announcements· May 4

Sensus Healthcare, Inc. (SRTS) has released its Q1 2023 Earnings Call Transcript, providing insight into the company's recent financial performance.
Alliance Global Partners has maintained a Buy recommendation for Sensus Healthcare (SRTS), indicating a positive outlook on the company's prospects.
SRTS has been highlighted as a notable stock in the finance and trading community, with its ticker symbol appearing in relevant discussions and articles.

Technical Analysis· Feb 26

The $SRTS stock exhibited a "Repeated high" pattern, which is a bearish sign, as it suggests manipulation and a potential reversal.
A short position was taken on $SRTS due to its suspicious price action, including an instant 10% vwap reclaim on low volume, which is not typical of a market in control by sellers.
The stock's cup and handle pattern has broken out, and it has also shown rising momentum and a positive Parabolic SAR, indicating a potential bullish trend.

Generated by AI

Community

Of the messages about SRTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	70.83%	59.29%
Newcomers	0%	0%	29.17%	40.71%

Regulars· May 10

Sensus Healthcare's Q1 revenue tripled year-over-year to $10.7M, beating estimates, and the company achieved a substantial profit.
The company's acquisition of a 60% stake in three radiation therapy centers is expected to generate $9-10M in annual revenue and net income.
Sensus Healthcare's Q1 EPS was 14c, beating estimates of 5c, and the company's CEO attributes the strong results to more than tripling revenues compared to the 2023 quarter.

Newcomers· Nov 14

Newcomers are expecting positive earnings from Sensus Healthcare, Inc. based on the stock's recent price increase.
Sensus Healthcare, Inc.'s Q3 revenue and net income have been reported as $8.839M and $1.215M, respectively.
The company's Q3 adjusted EBITDA and pretax profit have more than doubled compared to the same period in 2023.

Generated by AI

News

Sensus Healthcare director Eric Sachetta buys $66,682 in stock

1mo agoInvesting.com

Sensus Healthcare director Eric Sachetta buys $112,904 in stock

1mo agoInvesting.com

Sensus (SRTS) Q2 2026 Earnings Call Transcript

Detailed price information for Sensus Healthcare Inc (SRTS-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Sensus Healthcare Inc (SRTS) (Q2 2026) Earnings Call Highlights: Strong Pipeline and New CPT ...

Company secures delayed orders and sees growing international demand, positioning for a stronger second half.

1mo agofinance.yahoo.com

Sensus Healthcare, Inc. Q2 2026 Earnings Call Summary

Moby summary of Sensus Healthcare, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Sensus Healthcare Q2 Earnings Call Highlights

Sensus Healthcare (NASDAQ:SRTS) reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June. Chairman and Chief Executive Officer Joe Sard

1mo agoYahoo Finance

Also Discussed

Investors talking about SRTS also mention

#	Name	Attention
1	Lantheus Holdings Inc.LNTH	0%0
2	Lixte Biotechnology Holdings Inc.LIXT	0%new
3	CPI Aerostructures IncCVU	0%0
4	PETQ - PetIQ, Inc.	——
5	Blue Bird CorporationBLBD	0%new
6	Crexendo Inc.CXDO	0%new
7	Ultralife CorporationULBI	0%0
8	BK Technologies Corporation Common StockBKTI	0%0
9	Bel Fuse Inc. Class B Common StockBELFB	0%new
10	Clearfield, Inc.CLFD	0%0

Sensus Healthcare Inc.

Healthcare
Medical Devices

Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological skin conditions. The company develops and commercializes superficial radiation therapy systems that use low-energy X-ray technology to treat conditions such as non-melanoma skin cancers and keloids. Its product portfolio includes the SRT-100, SRT-100+, and SRT-100 Vision systems, along with related service and support offerings for healthcare providers. Sensus Healthcare serves dermatology and other clinical practices that seek targeted treatment options for superficial skin lesions and scar management. Based in Boca Raton, Florida, the company operates in the medical technology market with a focus on specialized radiation-based solutions for skin care applications.

Website

Location

851 Broken Sound Parkway NW

Boca Raton, FL, 33487

United States

Social

What share of all stock conversation is about SRTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 13

Sensus Healthcare's (SRTS) Q42025 results fell short of market predictions, leading to a decline in stock price.
The decline is seen as positive for the company's future, as it reflects a strategic transition to diversified recurring models, including FDA treatments and direct sales.
Sensus Healthcare delivered 11,411 FDA treatments to 922 patients in 2025, a significant increase from 1,367 treatments delivered to 264 patients in 2024.

Generated by AI

Sentiment

Of the messages about SRTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.74% +2.4
Bearish	—	—	0% 0	5.26% -2.4

Bullish· Feb 6

The company's earnings report was "amazing" and the stock is expected to reach $10+ by the end of the year.
The company has a strong story, with near 0 dilution, no debt, and profitable quarters, and is navigating through hard times with a new FDA model that will take time to generate revenue.
The company's valuation is low, making it a buy despite the recent earnings report being lower than expected.

Bearish· Feb 6

Sensus Healthcare, Inc. ($SRTS) is expected to experience a lull in revenue due to its transition to the Fair Trade revenue-sharing model, with management providing no guidance on the timing of the ramp-up.
The company's reliance on a single customer, SkinCure, is a concern, as it limits the potential for growth and creates a vulnerable position if SkinCure were to seek alternative device sources.
Sensus Healthcare's earnings release was met with disappointment, as the company missed earnings estimates and guided to a weak Q1, with sales expected to grow year-over-year in 2025 but only in the second half of the year.

Generated by AI

Topics

Of the messages about SRTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	80%
Earnings	0%	0%	0%	12.86%
Analysts	0%	0%	0%	1.43%
Controversies	0%	0%	0%	2.86%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	2.86%

Earnings· Nov 5

Sensus Healthcare, Inc. (SRTS) to release earnings after market close on Wednesday, with analysts expecting -0.05 EPS.
Earnings release timing aligns with market close on Wednesday.
Analysts' earnings expectations for SRTS are -$0.05 EPS.

Announcements· May 4

Sensus Healthcare, Inc. (SRTS) has released its Q1 2023 Earnings Call Transcript, providing insight into the company's recent financial performance.
Alliance Global Partners has maintained a Buy recommendation for Sensus Healthcare (SRTS), indicating a positive outlook on the company's prospects.
SRTS has been highlighted as a notable stock in the finance and trading community, with its ticker symbol appearing in relevant discussions and articles.

Technical Analysis· Feb 26

The $SRTS stock exhibited a "Repeated high" pattern, which is a bearish sign, as it suggests manipulation and a potential reversal.
A short position was taken on $SRTS due to its suspicious price action, including an instant 10% vwap reclaim on low volume, which is not typical of a market in control by sellers.
The stock's cup and handle pattern has broken out, and it has also shown rising momentum and a positive Parabolic SAR, indicating a potential bullish trend.

Generated by AI

Community

Of the messages about SRTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	70.83%	59.29%
Newcomers	0%	0%	29.17%	40.71%

Regulars· May 10

Sensus Healthcare's Q1 revenue tripled year-over-year to $10.7M, beating estimates, and the company achieved a substantial profit.
The company's acquisition of a 60% stake in three radiation therapy centers is expected to generate $9-10M in annual revenue and net income.
Sensus Healthcare's Q1 EPS was 14c, beating estimates of 5c, and the company's CEO attributes the strong results to more than tripling revenues compared to the 2023 quarter.

Newcomers· Nov 14

Newcomers are expecting positive earnings from Sensus Healthcare, Inc. based on the stock's recent price increase.
Sensus Healthcare, Inc.'s Q3 revenue and net income have been reported as $8.839M and $1.215M, respectively.
The company's Q3 adjusted EBITDA and pretax profit have more than doubled compared to the same period in 2023.

Generated by AI

Sensus Healthcare

Social

Feb 13

Bullish· Feb 6

Bearish· Feb 6

Earnings· Nov 5

Announcements· May 4

Technical Analysis· Feb 26

Regulars· May 10

Newcomers· Nov 14

Sensus Healthcare director Eric Sachetta buys $66,682 in stock

Sensus Healthcare director Eric Sachetta buys $112,904 in stock

Sensus (SRTS) Q2 2026 Earnings Call Transcript

Sensus Healthcare Inc (SRTS) (Q2 2026) Earnings Call Highlights: Strong Pipeline and New CPT ...

Sensus Healthcare, Inc. Q2 2026 Earnings Call Summary

Sensus Healthcare Q2 Earnings Call Highlights

Also Discussed

Sensus Healthcare Inc.

Company Information

Location

Sensus Healthcare director Eric Sachetta buys $66,682 in stock

Sensus Healthcare director Eric Sachetta buys $112,904 in stock

Sensus (SRTS) Q2 2026 Earnings Call Transcript

Sensus Healthcare Inc (SRTS) (Q2 2026) Earnings Call Highlights: Strong Pipeline and New CPT ...

Sensus Healthcare, Inc. Q2 2026 Earnings Call Summary

Sensus Healthcare Q2 Earnings Call Highlights

Also Discussed

Social

Feb 13

Bullish· Feb 6

Bearish· Feb 6

Earnings· Nov 5

Announcements· May 4

Technical Analysis· Feb 26

Regulars· May 10

Newcomers· Nov 14